Aldeyra Therapeutics (ALDX) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. QGEN
7. CSX
8. LRCX
9. NDAQ
10. BFH

Go back to Aldeyra Therapeutics (ALDX) Misses Q2 EPS by 4c

Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights

August 5, 2021 7:00 AM EDT

Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Clinical Trials of Reproxalap in Dry Eye Disease Expected in Fourth Quarter of 2021 U.S. FDA Grants Orphan Drug Designation to ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma and Retinitis Pigmentosa Initial Results from Phase 2 Clinical Trials of Oral RASP Inhibitor ADX-629 in Multiple Systemic Indications Anticipated in Fourth Quarter of 2021 or First Quarter of 2022 Cash and Cash Equivalents of $249.7 Million as of June 30, 2021; Projected Cash Runway Through 2023, Including Potential New Drug Applications; Initial Commercialization of Reproxalap, if Approved; and Continued... More